Methyl 2-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-3-methyl-1,2-oxazol-5-yl]benzoyl]amino]-2-phenylacetate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Methyl 2-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-3-methyl-1,2-oxazol-5-yl]benzoyl]amino]-2-phenylacetate
• 英文别名: methyl 2-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-3-methyl-1,2-oxazol-5-yl]benzoyl]amino]-2-phenylacetate
• 化学式: C₂₉H₂₆ClN₃O₆
• 分子量: 548.0
• InChiKey: BHIIAMNQEGYNFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  39
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  120
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Heterocyclic compounds useful in the treatment of disease
  申请人：EPIGEN BIOSCIENCES, INC.

  公开号：US10570103B2

  公开（公告）日：2020-02-25

  A method for treating a lysophosphatidic acid-dependent disease or condition in a subject in need thereof is provided. The method includes administering to the subject a therapeutically effective amount of a heterocyclic compound. The heterocyclic compound is a lysophosphatidic acid receptor ligand. Lysophosphatidic acid-dependent diseases and conditions include diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain.

  本发明提供了一种治疗溶血磷脂酸依赖性疾病或病症的方法。 该方法包括向受试者施用治疗有效量的杂环化合物。 杂环化合物是溶血磷脂酸受体配体。 溶血磷脂酸依赖性疾病和病症包括涉及纤维化的疾病，如心脏、肾脏、肝脏和肺的纤维化以及硬皮病；炎症性疾病，如糖尿病肾病和炎症性肠病；眼部疾病，如涉及视网膜变性的疾病；神经疾病，如瘙痒和疼痛。
• HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE
  申请人：Epigen Biosciences, Inc.

  公开号：EP2988743A2

  公开（公告）日：2016-03-02
• Heterocyclic Compounds Useful In The Treatment Of Disease
  申请人：EPIGEN BIOSCIENCES, INC.

  公开号：US20190135767A1

  公开（公告）日：2019-05-09

  A method for treating a lysophosphatidic acid-dependent disease or condition in a subject in need thereof is provided. The method includes administering to the subject a therapeutically effective amount of a heterocyclic compound. The heterocyclic compound is a lysophosphatidic acid receptor ligand. Lysophosphatidic acid-dependent diseases and conditions include diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain.